14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
BLLN vs SHC: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Sotera Health Company (SHC) is the stronger overall head-to-head candidate over BillionToOne, Inc. (BLLN) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). BLLN carries a Unified Composite Score of 45.8/100 (HOLD) at $96.31 (61.3x Forward P/E, 10.2% operating margin), whereas SHC carries 63.1/100 (BUY) at $16.25 (15.3x Forward P/E, 36.8% operating margin).
Growth vs. Quality Trade-Off: SHC earns the overall head-to-head edge with a stronger Unified Composite Score (63.1/100 BUY vs. BLLN 45.8/100 HOLD) and 0.95β · 44% Vol risk profile, whereas BLLN leads top-line expansion (+47.2% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates.
Technical & Structure Timing Caution: BLLN is currently in a Breakdown options structure phase (RSI 34.4); meanwhile SHC is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 38.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on BLLN vs SHC. Trailing 12-month operating profitability (BLLN 10.2% vs SHC 36.8%) and valuation multiples (BLLN 61.3x vs SHC 15.3x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Diagnostics & Research value chain with $5.0B market capitalization and 10.2% operating margin.
OpEx & R&D Reinvestment61.2% of Rev ($267M)
90D Engineering Disclosures0 Published
SHC Moat ProfileHigh-Margin Pricing Power Moat
Diagnostics & Research Operator
Competes within the Diagnostics & Research value chain with $4.7B market capitalization and 36.8% operating margin.
OpEx & R&D Reinvestment17.8% of Rev ($219M)
90D Engineering Disclosures0 Published
Investor FAQ BLLN vs SHC Key Questions & Quantitative Answers
As of Nov 16, 2026, Sotera Health Company (SHC) is the stronger overall head-to-head candidate over BillionToOne, Inc. (BLLN) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). BLLN carries a Unified Composite Score of 45.8/100 (HOLD) at $96.31 (61.3x Forward P/E, 10.2% operating margin), whereas SHC carries 63.1/100 (BUY) at $16.25 (15.3x Forward P/E, 36.8% operating margin). Growth vs. Quality Trade-Off: SHC earns the overall head-to-head edge with a stronger Unified Composite Score (63.1/100 BUY vs. BLLN 45.8/100 HOLD) and 0.95β · 44% Vol risk profile, whereas BLLN leads top-line expansion (+47.2% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: BLLN is currently in a Breakdown options structure phase (RSI 34.4); meanwhile SHC is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 38.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
BLLN leads the Growth & Scale pillar: BLLN posts +47.2% YoY revenue growth and +220.0% YoY earnings growth on $437M TTM revenue (71.4% gross margin, 10.2% operating margin), compared with SHC at +4.4% YoY revenue growth and +17.6% YoY earnings growth on $1.23B TTM revenue (54.6% gross margin, 36.8% operating margin). On trailing 12-month operating scale, BLLN generates $437M in USD-normalized revenue versus $1.23B for SHC. In operating R&D and SG&A reinvestment, BLLN deploys 61.2% of Rev ($267M) (0 90-day corporate R&D disclosures) versus 17.8% of Rev ($219M) (0 disclosures) for SHC.
SHC screens cheaper on headline valuation multiples. BLLN trades at 61.3x Forward P/E, 114.3x Trailing P/E, N/M PEG, and 10.5x EV/Revenue (7.8% FCF margin), whereas SHC trades at 15.3x Forward P/E, 27.7x Trailing P/E, 1.68x PEG, and 3.9x EV/Revenue (47.5% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against BLLN (13.2% ROE) versus SHC (27.0% ROE) capital efficiency.
In options market volatility and institutional positioning, BLLN carries 113.8% implied volatility (26th %ile, Balanced (25th–60th %ile)), a 1.21x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.44β · 42% Vol realized risk). By comparison, SHC carries 56.1% implied volatility (6th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.95β · 44% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.